Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors, antagonists |
Mechanism HMGB1 inhibitors(High Mobility Group Protein B1 inhibitors), NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors), TLR4 antagonists(Toll like receptor 4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC29H36O15 |
InChIKeyFBSKJMQYURKNSU-ZLSOWSIRSA-N |
CAS Registry61276-17-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Nephropathies | Preclinical | China | 01 Sep 2024 | |
Diabetic Nephropathies | Preclinical | China | 01 Sep 2024 | |
Parkinson Disease | Preclinical | China | 01 Jul 2024 | |
Parkinson Disease | Preclinical | China | 01 Jul 2024 | |
Ischemic stroke | Preclinical | China | 01 Feb 2024 | |
Ischemic stroke | Preclinical | China | 01 Feb 2024 |